Gilead Brings Top Exec Out of Retirement

May 26, 2016

May 26, 2016.

Gilead Sciences this week announced the re-appointment of a former Executive Vice President, Kevin Young, who retired from the company in February 2014. Young has been appointed Chief Operating Officer, replacing Paul R. Carter, who assumed Young's position when he left.

“I am delighted to welcome Kevin back to Gilead in a full-time capacity. His contributions during his previous tenure, particularly his management of the introduction of eight novel therapies across diverse geographies, made a tremendous impact on the company. I have equally valued his continued engagement and significant contributions as an advisor to Gilead over the past two years,” said Dr. Milligan. “Kevin’s knowledge of Gilead’s business, all aspects of commercial operations and our therapeutic areas of focus, his commitment to operational excellence, and his leadership capabilities make him an obvious choice for the role of Chief Operating Officer.” - See more at: http://www.gilead.com/news/press-releases/2016/5/gilead-sciences-announces-appointment-of-kevin-young-cbe-as-chief-operating-officer-and-martin-silverstein-md-as-executive-vice-president-strategy#sthash.tM1Fzqp2.dpuf

John F. Milligan, Gilead's President and Chief Executive Officer, said: “I am delighted to welcome Kevin back to Gilead in a full-time capacity. His contributions during his previous tenure, particularly his management of the introduction of eight novel therapies across diverse geographies, made a tremendous impact on the company."

“I am delighted to welcome Kevin back to Gilead in a full-time capacity. His contributions during his previous tenure, particularly his management of the introduction of eight novel therapies across diverse geographies, made a tremendous impact on the company. I have equally valued his continued engagement and significant contributions as an advisor to Gilead over the past two years,” said Dr. Milligan. “Kevin’s knowledge of Gilead’s business, all aspects of commercial operations and our therapeutic areas of focus, his commitment to operational excellence, and his leadership capabilities make him an obvious choice for the role of Chief Operating Officer.” - See more at: http://www.gilead.com/news/press-releases/2016/5/gilead-sciences-announces-appointment-of-kevin-young-cbe-as-chief-operating-officer-and-martin-silverstein-md-as-executive-vice-president-strategy#sthash.tM1Fzqp2.dpuf “I am delighted to welcome Kevin back to Gilead in a full-time capacity. His contributions during his previous tenure, particularly his management of the introduction of eight novel therapies across diverse geographies, made a tremendous impact on the company. I have equally valued his continued engagement and significant contributions as an advisor to Gilead over the past two years,” said Dr. Milligan. “Kevin’s knowledge of Gilead’s business, all aspects of commercial operations and our therapeutic areas of focus, his commitment to operational excellence, and his leadership capabilities make him an obvious choice for the role of Chief Operating Officer.” - See more at: http://www.gilead.com/news/press-releases/2016/5/gilead-sciences-announces-appointment-of-kevin-young-cbe-as-chief-operating-officer-and-martin-silverstein-md-as-executive-vice-president-strategy#sthash.tM1Fzqp2.dpuf “I am delighted to welcome Kevin back to Gilead in a full-time capacity. His contributions during his previous tenure, particularly his management of the introduction of eight novel therapies across diverse geographies, made a tremendous impact on the company. I have equally valued his continued engagement and significant contributions as an advisor to Gilead over the past two years,” said Dr. Milligan. “Kevin’s knowledge of Gilead’s business, all aspects of commercial operations and our therapeutic areas of focus, his commitment to operational excellence, and his leadership capabilities make him an obvious choice for the role of Chief Operating Officer.” - See more at: http://www.gilead.com/news/press-releases/2016/5/gilead-sciences-announces-appointment-of-kevin-young-cbe-as-chief-operating-officer-and-martin-silverstein-md-as-executive-vice-president-strategy#sthash.tM1Fzqp2.dpuf

The company also appointed Martin Silverstein as Executive Vice President, Strategy.